Postbiotics: An Emerging and Promising Class of Biologics
Remember how the elderly often recommend yogurt after a gastrointestinal infection? The yogurt matrix contains bio-actives that help regulate both innate and adaptive immunity by altering circulating and systemic biomarkers, as well as changing the gut microbiome. Which, in turn, strengthens the intestinal barrier and immune cell profile (1). These positive effects arise from both natural nutrients and fermentation-derived bioactive from probiotics or starter cultures.
These fermentation-derived bioactives are referred to as postbiotics, which include metabolites, short-chain fatty acids (SCFAs), microbial cell fractions, functional proteins, extracellular polysaccharides (EPS), cell lysates, teichoic acids, peptidoglycan-derived muropeptides, and pili-type structures (2).
Probiotic-derived postbiotics are purified and marketed as food and pharmaceutical products, such as Reuterin®, Del-Immune V®, Lacteol™, and Colimil® Baby to name a few (3). Their therapeutic effects mirror those of the source probiotics, offering immune modulation, antimicrobial properties, lowering cholesterol and blood pressure, and potential anti-cancer activities (4, 5). However, the selection of the probiotic fraction and its effective purification determines their therapeutic outcomes which include prevention and even treatment of medical conditions.
So, why purify postbiotics from probiotics?
Postbiotics offer a more stable alternative to live probiotics and also rule out the risk of bacteremia. They outperform naturally fermented products by consumption convenience and increased efficiency due to purification, without any food-related side effects, such as those associated with fermented milk and pickled foods (6). Evaluating their therapeutic efficacy and quality is dependent on their intended application. Products intended for food must adhere to food safety standards, while those meant for pharmaceuticals should follow specific pharmaceutical guidelines.
While many postbiotics are available in the market for preventing or treating various diseases, the field is still largely exploratory (7).
Recommended by LinkedIn
Explore emerging therapeutics, the latest aadvances in biopharmaceuticals, regulatory perspectives and much more at Biologics Conference 2025. From key academic leaders, industry experts to govt representatives, and regulatory bodies - everyone is going to be there! Join us for this exciting meeting of the scientific community!
For more information, visit our website: www.biologicsworkshop.com
Author: Tanvi Sawant , PhD Scholar, Nanomedicine Research Group, ICTMumbai
References: